AU Stocks
US Stocks
US Options
Emerging Asia
Cash Management
Margin Lending
Smart Portfolio
MoneybullR
RAPT
Rapt Therapeutics, Inc.
4.00
-0.04-0.99%Opening14:35 05/20 EDT
OPEN/PREV CLOSE4.060/4.040
TODAY RANGE3.952-4.100
VOL453.15K
MARKET CAP139.61M
52 WEEK RANGE3.952-27.35
AVG VOL (3M)1.53M
% TURNOVER1.30%
TURNOVER0
P/E (TTM)-1.3021
% RANGE3.66%
EPS(TTM)-3.0720
P/E(FORWARD)-1.2653
P/B1.064
BVPS3.760
DIVIDEND--
P/S830.62
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP132.06M
SHARES OUTSTANDING34.90M
NEXT EARNINGS08/09-08/13
FREE FLOAT33.02M
LOT SIZE1
EX-DIV DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·10h ago
RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
Seeking Alpha·5d ago
Wolfe downgrades RAPT, but still sees "immense" upside potential
Benzinga·6d ago
Wolfe Research Downgrades RAPT Therapeutics to Peer Perform
Seeking Alpha·05/10 14:50
RAPT falls for second day as Guggenheim, Barclays downgrade stock
Dow Jones·05/10 13:30
Rapt Therapeutics Cut to Equal-Weight From Overweight by Barclays
Dow Jones·05/10 13:30
Rapt Therapeutics Price Target Cut to $4.00/Share From $13.00 by Barclays
Benzinga·05/10 13:21
Barclays Downgrades RAPT Therapeutics to Equal-Weight, Lowers Price Target to $4
Dow Jones·05/10 10:39
Rapt Therapeutics Cut to Neutral From Buy by Guggenheim
Reuters·05/10 10:33
RAPT THERAPEUTICS, INC. <RAPT.O>: BARCLAYS CUTS TARGET PRICE TO $4 FROM $13
Reuters·05/10 10:33
RAPT THERAPEUTICS INC <RAPT.O>: GUGGENHEIM CUTS TO NEUTRAL RATING
Benzinga·05/10 10:29
Guggenheim Downgrades RAPT Therapeutics to Neutral
Same Industry
Name/Symbol
Change%
Price